These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 38472366)

  • 1. Organotypic culture of human brain explants as a preclinical model for AI-driven antiviral studies.
    Partiot E; Gorda B; Lutz W; Lebrun S; Khalfi P; Mora S; Charlot B; Majzoub K; Desagher S; Ganesh G; Colomb S; Gaudin R
    EMBO Mol Med; 2024 Apr; 16(4):1004-1026. PubMed ID: 38472366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Organotypic lung tissue culture as a preclinical model to study host- influenza A viral infection: A case for repurposing of nafamostat mesylate.
    Saglam-Metiner P; Yildiz-Ozturk E; Tetik-Vardarli A; Cicek C; Goksel O; Goksel T; Tezcanli B; Yesil-Celiktas O
    Tissue Cell; 2024 Apr; 87():102319. PubMed ID: 38359705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of 3D Human Intestinal Organoids as a Platform for EV-A71 Antiviral Drug Discovery.
    Masmoudi F; Santos-Ferreira N; Pajkrt D; Wolthers KC; DeGroot J; Vlaming MLH; Rocha-Pereira J; Buti L
    Cells; 2023 Apr; 12(8):. PubMed ID: 37190047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis C Virus and Antiviral Drug Resistance.
    Kim S; Han KH; Ahn SH
    Gut Liver; 2016 Nov; 10(6):890-895. PubMed ID: 27784846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunosuppressive and antiviral treatment of hepatitis C virus-associated glomerular disease: A long-term follow-up.
    Fabrizi F; Aghemo A; Lampertico P; Fraquelli M; Cresseri D; Moroni G; Passerini P; Donato FM; Messa P
    Int J Artif Organs; 2018 Jun; 41(6):306-318. PubMed ID: 29595085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies.
    Zeisel MB; Fofana I; Fafi-Kremer S; Baumert TF
    J Hepatol; 2011 Mar; 54(3):566-76. PubMed ID: 21146244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Mechanisms of Antiviral Agents against Dengue Virus.
    Lee MF; Wu YS; Poh CL
    Viruses; 2023 Mar; 15(3):. PubMed ID: 36992414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Priming of Antiviral CD8 T Cells without Effector Function by a Persistently Replicating Hepatitis C-Like Virus.
    Hartlage AS; Walker CM; Kapoor A
    J Virol; 2020 May; 94(10):. PubMed ID: 32102885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AI-Accelerated Design of Targeted Covalent Inhibitors for SARS-CoV-2.
    Joshi RP; Schultz KJ; Wilson JW; Kruel A; Varikoti RA; Kombala CJ; Kneller DW; Galanie S; Phillips G; Zhang Q; Coates L; Parvathareddy J; Surendranathan S; Kong Y; Clyde A; Ramanathan A; Jonsson CB; Brandvold KR; Zhou M; Head MS; Kovalevsky A; Kumar N
    J Chem Inf Model; 2023 Mar; 63(5):1438-1453. PubMed ID: 36808989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained virologic response by direct-acting antivirals suppresses skeletal muscle loss in hepatitis C virus infection.
    Endo K; Sato T; Suzuki A; Yoshida Y; Kakisaka K; Miyasaka A; Takikawa Y
    J Gastroenterol Hepatol; 2020 Sep; 35(9):1602-1609. PubMed ID: 31975438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Artificial intelligence predicts direct-acting antivirals failure among hepatitis C virus patients: A nationwide hepatitis C virus registry program.
    Lu MY; Huang CF; Hung CH; Tai CM; Mo LR; Kuo HT; Tseng KC; Lo CC; Bair MJ; Wang SJ; Huang JF; Yeh ML; Chen CT; Tsai MC; Huang CW; Lee PL; Yang TH; Huang YH; Chong LW; Chen CL; Yang CC; Yang SS; Cheng PN; Hsieh TY; Hu JT; Wu WC; Cheng CY; Chen GY; Zhou GX; Tsai WL; Kao CN; Lin CL; Wang CC; Lin TY; Lin CL; Su WW; Lee TH; Chang TS; Liu CJ; Dai CY; Kao JH; Lin HC; Chuang WL; Peng CY; Tsai CW; Chen CY; Yu ML;
    Clin Mol Hepatol; 2024 Jan; 30(1):64-79. PubMed ID: 38195113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Compound SBI-0090799 Inhibits Zika Virus Infection by Blocking
    Riva L; Goellner S; Biering SB; Huang CT; Rubanov AN; Haselmann U; Warnes CM; De Jesus PD; Martin-Sancho L; Terskikh AV; Harris E; Pinkerton AB; Bartenschlager R; Chanda SK
    J Virol; 2021 Oct; 95(22):e0099621. PubMed ID: 34468177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Korean medicinal plant extracts exhibit antiviral potency against viral hepatitis.
    Jacob JR; Korba BE; You JE; Tennant BC; Kim YH
    J Altern Complement Med; 2004 Dec; 10(6):1019-26. PubMed ID: 15673997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of drug-drug interactions on effectiveness and safety of direct-acting antivirals against hepatitis C virus.
    Margusino-Framiñán L; Cid-Silva P; Giménez-Arufe V; Mondelo-García C; Fernández-Oliveira C; Mena-de-Cea Á; Martín-Herranz I; Castro-Iglesias Á
    Eur J Hosp Pharm; 2021 Jan; 28(1):16-21. PubMed ID: 33355279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modular cell-based platform for high throughput identification of compounds that inhibit a viral interferon antagonist of choice.
    Vasou A; Paulus C; Narloch J; Gage ZO; Rameix-Welti MA; Eléouët JF; Nevels M; Randall RE; Adamson CS
    Antiviral Res; 2018 Feb; 150():79-92. PubMed ID: 29037975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Replicons of a Rodent Hepatitis C Model Virus Permit Selection of Highly Permissive Cells.
    Wolfisberg R; Holmbeck K; Nielsen L; Kapoor A; Rice CM; Bukh J; Scheel TKH
    J Virol; 2019 Oct; 93(19):. PubMed ID: 31292246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current status and future development of infectious cell-culture models for the major genotypes of hepatitis C virus: Essential tools in testing of antivirals and emerging vaccine strategies.
    Ramirez S; Bukh J
    Antiviral Res; 2018 Oct; 158():264-287. PubMed ID: 30059723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting proteostasis of the HEV replicase to combat infection in preclinical models.
    Zhang F; Xu LD; Zhang Q; Wang A; Yu X; Liu S; Chen C; Wu S; Jin J; Lin A; Neculai D; Zhao B; Feng XH; Liang T; Xu P; Huang YW
    J Hepatol; 2023 Apr; 78(4):704-716. PubMed ID: 36574921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial uptake, time to treatment, and real-world effectiveness of all-oral direct-acting antivirals for hepatitis C virus infection in the United States: A retrospective cohort analysis.
    Kwo PY; Puenpatom A; Zhang Z; Hui SL; Kelley AA; Muschi D
    PLoS One; 2019; 14(8):e0218759. PubMed ID: 31437170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multi-scale model for hepatitis C viral load kinetics under treatment with direct acting antivirals.
    Clausznitzer D; Harnisch J; Kaderali L
    Virus Res; 2016 Jun; 218():96-101. PubMed ID: 26409026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.